MRSN vs. KRRO, PRME, NVCT, ACIU, BTMD, ELDN, ZYBT, YMAB, SOPH, and LFVN
Should you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include Korro Bio (KRRO), Prime Medicine (PRME), Nuvectis Pharma (NVCT), AC Immune (ACIU), biote (BTMD), Eledon Pharmaceuticals (ELDN), Zhengye Biotechnology (ZYBT), Y-mAbs Therapeutics (YMAB), SOPHiA GENETICS (SOPH), and LifeVantage (LFVN). These companies are all part of the "pharmaceutical products" industry.
Mersana Therapeutics vs.
Korro Bio (NASDAQ:KRRO) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, community ranking, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.
13.2% of Korro Bio shares are held by institutional investors. Comparatively, 93.9% of Mersana Therapeutics shares are held by institutional investors. 5.4% of Korro Bio shares are held by insiders. Comparatively, 11.8% of Mersana Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Korro Bio has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -214.20%. Korro Bio's return on equity of -50.25% beat Mersana Therapeutics' return on equity.
Mersana Therapeutics received 226 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 66.14% of users gave Mersana Therapeutics an outperform vote.
Korro Bio presently has a consensus target price of $136.33, suggesting a potential upside of 641.75%. Mersana Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 974.69%. Given Mersana Therapeutics' higher possible upside, analysts clearly believe Mersana Therapeutics is more favorable than Korro Bio.
Korro Bio has higher earnings, but lower revenue than Mersana Therapeutics. Korro Bio is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.
Korro Bio has a beta of 2.13, indicating that its stock price is 113% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.
In the previous week, Korro Bio had 11 more articles in the media than Mersana Therapeutics. MarketBeat recorded 13 mentions for Korro Bio and 2 mentions for Mersana Therapeutics. Mersana Therapeutics' average media sentiment score of 1.43 beat Korro Bio's score of 0.32 indicating that Mersana Therapeutics is being referred to more favorably in the news media.
Summary
Korro Bio beats Mersana Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Mersana Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mersana Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MRSN) was last updated on 3/28/2025 by MarketBeat.com Staff
Buy MRSN Stock Free MRSN Stock Alerts